<DOC>
	<DOCNO>NCT01411579</DOCNO>
	<brief_summary>One recent interesting field diagnostic image diffusion-weighted MR imaging ( DW-MRI ) . Various study evaluate application DW-MRI diffuse liver disease focal liver lesion provide controversial result , probably due difficult reproducibility apparent diffusion coefficient ( ADC ) measurement . It conceivable wide inter/intra-individual variability actually exist apparent diffusion coefficient ( ADC ) -values , apparent diffusion coefficient ( ADC ) -value present higher reliability measure temporal change water diffusion within individual ( longitudinal-evaluation ) , characterize tissue different patient ( transverse-evaluation ) . For reason , previous study assess application DW-MRI predicting chemotherapy ( CHT ) outcome liver metastasis . The rationale study overt biochemical change show neoplastic cell CHT sensitivity DW-MRI identification change . The author notice metastatic lesion low ADC-values present also best outcome CHT . Moreover , study suggest could possible assess single patient respond ( R ) ( NR ) CHT liver DW-MRI perform 3 day 3 week begin CHT .</brief_summary>
	<brief_title>Use DwI-MR Predict Chemotherapy Response Liver Metastases Hepatocarcinoma</brief_title>
	<detailed_description>In R patient increase mean diameter neoplastic cell present first week CHT consequent reduction ADC-value . Then , ADC-value increase 2-3 week due reduction cellular volume increase membrane permeability . In NR patient , biochemical change present consequent constant ADC-value before/after CHT . Our multicentre study allow recruitment high number patient vs. previous study . Moreover , presently outcome CHT liver metastasis evaluate 2-3 cycle CHT accord RECIST ( Response-Evaluation-Criteria-In-Solid-Tumors ) merely dimensional basis . Anyway , frequently liver metastasis R patient , show significant dimensional change , present several biochemical/metabolic change , include RECIST , probably detectable DW-MRI . The principal objective study early assessment CHT outcome liver metastasis advance hepatocellular carcinoma ( HCC ) . Patients liver metastasis stratify R NR basis contrast-enhanced CT examination perform 20 day begin second cycle CHT ; patient HCC undergoing therapy Sorafenib stratify R NR basis contrast-enhanced CT examination perform 90 day begin therapy . The ADC-values obtain first CHT cycle compare patient category ass grade agreement dimensional functional parameter . Moreover , investigator ' aim ass whether liver metastasis HCCs present low ADC-value CHT actually responsive CHT comparison liver metastases HCCs present high ADC-value . Secondary objective : propose additional functional criterion RECIST 1.1 mRECIST ( HCC ) criterion base water diffusion biochemical change neoplastic cell . As objective possible hypothesize different response CHT different tumor histotypes detectable different ADC change induce CHT . Patient population Inclusion criterion : - age , compliant , patient enrol CHT , without major contraindication MR examination ; - non-confluent liver metastasis , every primary carcinoma histotype biopsy/surgical-proven , without intralesional necrosis/calcification involve &gt; 30 % volume ; - multiple confluent hepatocellular carcinoma , histotype biopsy/surgical-proven prevision treatment Sorafenib ; - least one marker lesion allow reproducible ADC measurement , i.e . place level lower right liver segment ; - detection/enrolment contrast-enhanced CT CHT allow define lesion size gross parenchymal involvement ( HCC ) . Each patient sign inform consent , procedure completely explain . For metastasis : three diameter marker lesion measure , mean/minimal/maximal ADC±standard deviation quantify region-of-interests ( ROIs ) place within lesion avoid lesion margin necrotic/intratumoral calcification area . All measurement repeat three time even level adjacent liver parenchyma ( within 3 cm lesion margin , keep ROI diameter &gt; 2 cm ) . Consequently , absolute value ( s/mm2 ) ADC , ADC percentages vs. adjacent liver parenchyma measure different time compare . For HCC : three diameter gross parenchymal involvement measure , mean/minimal/maximal ADC±standard deviation quantify large region-of-interests ( ROIs ) place within liver lobe contain involvement . All measurement repeat three time even level adjacent normal liver parenchyma ( within 3 cm lesion margin , keep ROI diameter &gt; 2 cm ) . Consequently , absolute value ( s/mm2 ) ADC , ADC percentages vs. adjacent liver parenchyma measure different time compare . Imaging For metastasis : patient scan DW-MRI contrast-enhanced CT begin CHT ( Time 0 ) . The time initial MRI contrast-enhanced CT superior one week . MRI examination repeat within one week ( Time 1 ) 20 day begin first cycle CHT ( Time 2 ) , 20 day begin second cycle CHT ( Time 3 ) . For HCC : patient scan DW-MRI contrast-enhanced CT begin CHT ( Time 0 ) . The time initial MRI contrast-enhanced CT superior one week . MRI examination repeat 30 day ( Time 1 ) , 60 day 90 day ( Time 3 ) begin CHT . Contrast-enhanced CT perform contemporarily within one week last MRI examination . Contrast-enhanced CT examination perform accord establish protocol use 16/64-row equipment accord centre involve , contrast bolus-track technology , slice- thickness reconstruction 3 mm , before/after ev . injection iodinate contrast agent ( 3 mL/s ) , arterial/portal phase . All MR examination carry use follow 1.5-T unit : - Gyroscan ACS NT Intera Release 12 ( Philips , Eindhoven , The Netherlands ) ( Trieste Florence ) , gradient strength , 30 mT/m ; slew rate , 120 T/m/s ; six-channel phase array multicoil ; - Magnetom Avanto ( Siemens , Erlangen , Germany ) ( Treviso Napoli ) , gradient strength , 45 mT/m ; slew rate , 200 T/m/s ; 2 phased-array coil 18 element . The different MR equipment employ different center calibrate dedicated phantom . The phased array multicoil adequately position cover upper abdomen subject lie supine position , arm extend head avoid artifact . Patients , fast 4 hour , instruct maintain constant respiration depth , even possibility use exogenous oxygen delivery avoid deep respiration . All acquisition obtain single-shot sequence obtain immediately/automatically ADC-values . The protocol include following acquisition : 1 . T2-weighted half-Fourier single-shot turbo spin-echo ( HASTE ) free-breath sequence ; transverse/coronal plane ; TR/TE , 810/80 m ; echo-train length , 69 ; slice number , 40 ; slice thickness , 5 mm ; intersection gap , 10 % ; field view , 300-420 mm ; effective matrix size , 256 x 165 ; number signal average ( NSA ) , 1 ; total acquisition time , 2-3 min ; 2 . T1-weighted 2D gradient echo in/out phase breath-hold sequence ; transverse plane ; TR/TE , 231-121/ 14.6-2.3 m ; slice thickness , 5 mm ; slice number , 24 ; intersection gap,10 % ; flip angle , 80° ; sense factor , 1.5 ; field view , 300-420 mm ; effective matrix size , 256 x 165 ; NSA , 1 ; total acquisition time , 18 ; 3 . D-weighted echo-planar imaging ( EPI ) single-shot free-breath sequence acquire transverse plane variable EPI factor follow parameter . Fat suppression obtain spectral pre-saturation inversion recovery . Isotropic motion probe gradient apply DwI acquisition b-value obtain image correspond ADC map . The investigator presently define R patient show reduction liver metastasis HCC diameter ≥30 % contrast-enhanced CT three week begin second CHT cycle ; , consider NR . Changes tumor size treatment calculate use formula % Vend = ( VB -Vend ) /VBx100 , VB lesion size treatment ( maximum transverse diameter ) Vend lesion size 20 day second administration . On basis dimensional reduction liver metastases parenchymal involvement ( HCC ) contrast-enhanced CT Time 3 vs. Time 0 scan , patient classify R NR accord RECIST mRECIST criterion . Afterwards , basis ADC-values measure different MR examination , inter/intra-individual ADC-values compare result contrast-enhanced CT ass relation reduction liver metastasis diameter : - increase ADC-value Time 3 ( end CHT ) ; - reduction ADC-value Time 1 ( early assessment ) ; - increase ADC-value Time 2 ( early assessment ) ; ass whether lesion high pre-treatment ADC-value present also high dimensional reduction high ADC-value end CHT ; In center evaluation perform three time two blind observer ( trained place ROI inter-centre conference ) ass reproducibility measurement . The observer assess MR image different observer assess CT image aware size change CHT . The investigator perform data mathematical fitting multi-b DW-MRI data set calculate true diffusion perfusion fraction . Statistical analysis employ linear regression analysis ass association ADC-value change CHT outcome . The transferability result present study clinical practice possible achievement primary objective , correspond possibility stratify patient R NR CHT DW-MRI one week treatment and/or pre-treatment ADC assessment . Nowadays , necessary wait 20-30 day end second third CHT cycle know individual outcome CHT . This determine 2-3 month ineffective therapy consequent avoidable pain patient related drug administration , unusable cost . The possibility know response patient CHT well advance allow avoid vain drug administration patient could attempt different treatment drug combination reduce treatment cost . The clinical transferability present study perform achievement one secondary objective , correspond identification functional criterion base water diffusion biochemical feature neoplastic cell propose additional alternative criterion RECIST 1.1 mRECIST , identification different response CHT different tumor histotypes . If one objectives reach study achieve important result , allow correct assessment individual response CHT .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Inclusion criterion : age , compliant , patient enrol CHT , without major contraindication MR examination ; nonconfluent liver metastasis , every primary carcinoma histotype biopsy/surgicalproven , without intralesional necrosis/calcification involve &gt; 30 % volume ; least one marker lesion allow reproducible ADC measurement , i.e . place level lower right liver segment ; multiple confluent hepatocellular carcinoma , histotype biopsy/surgicalproven prevision treatment Sorafenib ; detection/enrolment contrastenhanced CT CHT allow define lesion size gross parenchymal involvement ( HCC ) Each patient sign inform consent , procedure completely explain . For metastasis : Three diameter marker lesion measure , mean/minimal/maximal ADC±standard deviation quantify regionofinterests ( ROIs ) place within lesion avoid lesion margin necrotic/intratumoral calcification area . For hepatocarcinoma : Three diameter gross parenchymal involvement measure , mean/minimal/maximal ADC±standard deviation quantify large regionofinterests ( ROIs ) place within lobe contain involvement . All measurement repeat three time even level adjacent liver parenchyma ( within 3 cm lesion margin , keep ROI diameter &gt; 2 cm ) . Consequently , absolute value ( s/mm2 ) ADC , ADC percentages vs. adjacent liver parenchyma measure different time compare .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>liver</keyword>
	<keyword>metastasis</keyword>
	<keyword>hepatocarcinoma</keyword>
	<keyword>MR</keyword>
	<keyword>DWI</keyword>
	<keyword>chemotherapy</keyword>
</DOC>